Matica Biotechnology, Inc. is a contract development and manufacturing organization (CDMO) specializing in the production of virus-based cell & gene therapies, vaccines, and other precision medicines for our clients. Our GMP facility is currently under construction in College Station, TX, slated to open in Q3 2021.
While our facility may be new, we have assembled an exceptional staff of industry veterans, most with 10-15 years of experience in the production of virus and advanced therapies for some of the most innovative products on market and in the clinic today.
With the support of our parent company CHA Biotech, our goal is to establish a streamlined, global manufacturing solution for your viral vector product. Our single-use bioreactor platforms, remote monitoring systems, quality driven processes and dedicated staff come together to create an exceptional framework to ensure the product development and manufacturing process keeps pace with the often-accelerated clinical approval pathways to the patient bedside.